175 related articles for article (PubMed ID: 22938766)
1. The use of polymeric platinum(IV) prodrugs to deliver multinuclear platinum(II) drugs with reduced systemic toxicity and enhanced antitumor efficacy.
Xiao H; Song H; Zhang Y; Qi R; Wang R; Xie Z; Huang Y; Li Y; Wu Y; Jing X
Biomaterials; 2012 Nov; 33(33):8657-69. PubMed ID: 22938766
[TBL] [Abstract][Full Text] [Related]
2. Platinum (IV)-coordinate polymers as intracellular reduction-responsive backbone-type conjugates for cancer drug delivery.
Yang J; Liu W; Sui M; Tang J; Shen Y
Biomaterials; 2011 Dec; 32(34):9136-43. PubMed ID: 21889206
[TBL] [Abstract][Full Text] [Related]
3. A prodrug strategy to deliver cisplatin(IV) and paclitaxel in nanomicelles to improve efficacy and tolerance.
Xiao H; Song H; Yang Q; Cai H; Qi R; Yan L; Liu S; Zheng Y; Huang Y; Liu T; Jing X
Biomaterials; 2012 Sep; 33(27):6507-19. PubMed ID: 22727463
[TBL] [Abstract][Full Text] [Related]
4. Advances in platinum chemotherapeutics.
Harper BW; Krause-Heuer AM; Grant MP; Manohar M; Garbutcheon-Singh KB; Aldrich-Wright JR
Chemistry; 2010 Jun; 16(24):7064-77. PubMed ID: 20533453
[TBL] [Abstract][Full Text] [Related]
5. A dual-targeting hybrid platinum(IV) prodrug for enhancing efficacy.
Xiao H; Yan L; Zhang Y; Qi R; Li W; Wang R; Liu S; Huang Y; Li Y; Jing X
Chem Commun (Camb); 2012 Nov; 48(87):10730-2. PubMed ID: 23012698
[TBL] [Abstract][Full Text] [Related]
6. Biodegradable polymer - cisplatin(IV) conjugate as a pro-drug of cisplatin(II).
Xiao H; Qi R; Liu S; Hu X; Duan T; Zheng Y; Huang Y; Jing X
Biomaterials; 2011 Oct; 32(30):7732-9. PubMed ID: 21783244
[TBL] [Abstract][Full Text] [Related]
7. Mono- and di-bromo platinum(IV) prodrugs via oxidative bromination: synthesis, characterization, and cytotoxicity.
Xu Z; Wang Z; Yiu SM; Zhu G
Dalton Trans; 2015 Dec; 44(46):19918-26. PubMed ID: 26514681
[TBL] [Abstract][Full Text] [Related]
8. Optimization of (1,2-diamino-cyclohexane)platinum(II)-loaded polymeric micelles directed to improved tumor targeting and enhanced antitumor activity.
Cabral H; Nishiyama N; Kataoka K
J Control Release; 2007 Aug; 121(3):146-55. PubMed ID: 17628162
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, characterization, and cytotoxicity of dinuclear platinum-bisphosphonate complexes to be used as prodrugs in the local treatment of bone tumours.
Margiotta N; Ostuni R; Gandin V; Marzano C; Piccinonna S; Natile G
Dalton Trans; 2009 Dec; (48):10904-13. PubMed ID: 20023921
[TBL] [Abstract][Full Text] [Related]
10. A core cross-linked polymeric micellar platium(IV) prodrug with enhanced anticancer efficiency.
Hou J; Shang J; Jiao C; Jiang P; Xiao H; Luo L; Liu T
Macromol Biosci; 2013 Jul; 13(7):954-65. PubMed ID: 23744619
[TBL] [Abstract][Full Text] [Related]
11. In vitro biological evaluation of platinum(II) complexes with 1-(methoxy substituted benzyl) azetidine-3,3-dicarboxylato ligands.
Yin R; Gou S; Sun Y; Liu X
Bioorg Med Chem; 2012 Feb; 20(4):1461-7. PubMed ID: 22264764
[TBL] [Abstract][Full Text] [Related]
12. Anticancer platinum (IV) prodrugs with novel modes of activity.
Chin CF; Wong DY; Jothibasu R; Ang WH
Curr Top Med Chem; 2011; 11(21):2602-12. PubMed ID: 22039869
[TBL] [Abstract][Full Text] [Related]
13. Preparation of antitumor oxaliplatin/cisplatin docking dinuclear platinum complex.
Noji M; Kizu R; Takeda Y; Akiyama N; Yoshizaki I; Eriguchi M; Kidani Y
Biomed Pharmacother; 2005 Jun; 59(5):224-9. PubMed ID: 15919175
[TBL] [Abstract][Full Text] [Related]
14. Platinum(iv) prodrugs with long lipid chains for drug delivery and overcoming cisplatin resistance.
Chen Q; Yang Y; Lin X; Ma W; Chen G; Li W; Wang X; Yu Z
Chem Commun (Camb); 2018 May; 54(42):5369-5372. PubMed ID: 29744485
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
[TBL] [Abstract][Full Text] [Related]
16. Targeted iron nanoparticles with platinum-(IV) prodrugs and anti-EZH2 siRNA show great synergy in combating drug resistance in vitro and in vivo.
Yu C; Ding B; Zhang X; Deng X; Deng K; Cheng Z; Xing B; Jin D; Ma P; Lin J
Biomaterials; 2018 Feb; 155():112-123. PubMed ID: 29175080
[TBL] [Abstract][Full Text] [Related]
17. Nanoparticle-mediated delivery of multinuclear platinum(IV) prodrugs with enhanced drug uptake and the activity of overcoming drug resistance.
Gao Y; Jiang M; Ma Y; Wu S; Li W; Yang X; Li Y; Jing X; Jiang H
Anticancer Drugs; 2016 Feb; 27(2):77-83. PubMed ID: 26473527
[TBL] [Abstract][Full Text] [Related]
18. Oxidation of 3,6-dioxa-1,8-octanedithiol by platinum(IV) anticancer prodrug and model complex: kinetic and mechanistic studies.
Huo S; Shen S; Liu D; Shi T
J Phys Chem B; 2012 Jun; 116(22):6522-8. PubMed ID: 22574871
[TBL] [Abstract][Full Text] [Related]
19. Potent Chlorambucil-Platinum(IV) Prodrugs.
Aputen AD; Elias MG; Gilbert J; Sakoff JA; Gordon CP; Scott KF; Aldrich-Wright JR
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142383
[TBL] [Abstract][Full Text] [Related]
20. Emerging platinum(iv) prodrugs to combat cisplatin resistance: from isolated cancer cells to tumor microenvironment.
Wang Z; Deng Z; Zhu G
Dalton Trans; 2019 Feb; 48(8):2536-2544. PubMed ID: 30633263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]